Provided by Tiger Trade Technology Pte. Ltd.

Kazia Therapeutics Limited

6.44
-0.3800-5.57%
Post-market: 6.550.1100+1.71%17:37 EST
Volume:147.24K
Turnover:973.04K
Market Cap:73.00M
PE:-0.52
High:6.99
Open:6.72
Low:6.37
Close:6.82
52wk High:17.40
52wk Low:2.86
Shares:11.34M
Float Shares:10.58M
Volume Ratio:0.48
T/O Rate:1.39%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-12.3849
EPS(LYR):-12.3849
ROE:-3891.64%
ROA:-64.28%
PB:-13.11
PE(LYR):-0.52

Loading ...

Top Premarket Gainers

MT Newswires Live
·
Jan 05

NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 03:45 PM

Reuters
·
Jan 03

BRIEF-Kazia Therapeutics Regains Full Nasdaq Listing Compliance

Reuters
·
Dec 22, 2025

Kazia Therapeutics Raises $50 Million in Private Placement

Reuters
·
Dec 22, 2025

Kazia Therapeutics Limited : H.c. Wainwright Raises Target Price to $18 From $13

THOMSON REUTERS
·
Dec 12, 2025

Kazia Therapeutics Reports Paxalisib Shows Tumor Shrinkage and Immune Reinvigoration in Advanced Breast Cancer Trial

Reuters
·
Dec 10, 2025

What's Going On With Cancer Firm Kazia Therapeutics

Benzinga
·
Dec 03, 2025

BRIEF-Kazia Therapeutics Announces Pricing Of $50.0 Million Private Placement Of Equity Securities

Reuters
·
Dec 02, 2025

BUZZ-U.S. STOCKS ON THE MOVE-Viking, Valvoline, Alphabet

Reuters
·
Nov 20, 2025

BUZZ-Microcap Kazia shares soar 40% after positive drug update on single-patient treatment

Reuters
·
Nov 20, 2025

What Sparked Kazia Therapeutics' Over 51% After-Hours Surge?

Benzinga_recent_news
·
Nov 19, 2025

Kazia Therapeutics Reports Initial iCR in Metastatic TNBC and Advances Pipeline Programs

Reuters
·
Nov 19, 2025

Kazia Therapeutics reports A$42,000 revenue for fiscal year 2025

Reuters
·
Nov 08, 2025

Kazia Therapeutics Delays Annual Financial Report Filing

Reuters
·
Nov 01, 2025

BRIEF-Kazia Therapeutics To Request FDA Type C Meeting To Discuss Overall Survival Data In GBM And Potential NDA Filing In Alignment With FDA Initiative Project Frontrunner

Reuters
·
Oct 27, 2025

Kazia Therapeutics Ltd - Seeks FDA Feedback on Regulatory Pathway Under Project Frontrunner for Paxalisib

THOMSON REUTERS
·
Oct 27, 2025

Kazia Therapeutics to Request FDA Type C Meeting to Discuss Overall Survival Data in GBM and Potential Nda Filing in Alignment With FDA Initiative Project Frontrunner

THOMSON REUTERS
·
Oct 27, 2025

Kazia Therapeutics Enters Exclusive Collaboration with QIMR Berghofer to Develop First-in-Class PD-L1 Protein Degrader for Cancer Treatment

Reuters
·
Oct 08, 2025

BRIEF-Kazia Therapeutics Announces Collaboration And In-Licensing Agreement For First-In-Class PD-L1 Protein Degrader Program

Reuters
·
Oct 07, 2025

Kazia Therapeutics signs collaboration and in-licensing agreement for PD-L1

TIPRANKS
·
Oct 07, 2025